ICI’s Diprivan (propofol)
Executive Summary
ICI submitted general pediatric anesthesia studies of the anesthetic to FDA in May, not studies in pediatric ICU patients ("The Pink Sheet" Nov. 30, p. 10). The company voluntarily sent out a "Dear Doctor" letter in August warning that safety and effectiveness of Diprivan in pediatric ICU patients "has not been established" ("The Pink Sheet" Sept. 7, p. 14).